The estimated Net Worth of Bernd R. Seizinger is at least $120 ezer dollars as of 13 March 2024. Bernd Seizinger owns over 6,860 units of Aprea Therapeutics stock worth over $108,466 and over the last 5 years he sold APRE stock worth over $0. In addition, he makes $11,625 as Independent Director at Aprea Therapeutics.
Sign up
Bernd Seizinger APRE stock SEC Form 4 insiders trading
Bernd has made over 5 trades of the Aprea Therapeutics stock since 2019, according to the Form 4 filled with the SEC. Most recently he bought 6,860 units of APRE stock worth $50,009 on 13 March 2024.
The largest trade he's ever made was exercising 263,970 units of Aprea Therapeutics stock on 7 October 2019 worth over $18,478. On average, Bernd trades about 26,764 units every 125 days since 2019. As of 13 March 2024 he still owns at least 33,685 units of Aprea Therapeutics stock.
You can see the complete history of Bernd Seizinger stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Bernd Seizinger biography
Dr. Bernd R. Seizinger M.D., Ph.D. serves as Independent Director of the Company. Dr. Seizinger is a board member in a number of public and private biotech companies in the United States, Europe and Canada, including Oxford BioTherapeutics Ltd., Vaccibody AS, BioInvent International AB, Oncolytics Biotech, Inc. and CryptoMedix LLC. Previously, Dr. Seizinger was President and Chief Executive Officer of GPC Biotech, VP Oncology Drug Discovery at Bristol-Myers Squibb Company, and Executive VP and Chief Scientific Officer at Genome Therapeutics. Prior to his corporate appointments, he held senior faculty positions at Massachusetts Harvard Medical School, Massachusetts General Hospital and Princeton University. Seizinger is qualified to serve on our Board because of his perspective and experience as a leader and board member in the life sciences industry, as well as his strong medical and scientific background.
What is the salary of Bernd Seizinger?
As the Independent Director of Aprea Therapeutics, the total compensation of Bernd Seizinger at Aprea Therapeutics is $11,625. There are 7 executives at Aprea Therapeutics getting paid more, with Christian Schade having the highest compensation of $3,677,570.
How old is Bernd Seizinger?
Bernd Seizinger is 64, he's been the Independent Director of Aprea Therapeutics since 2015. There are 1 older and 15 younger executives at Aprea Therapeutics. The oldest executive at Aprea Therapeutics, Inc. is Guido Magni, 67, who is the Independent Director.
Insiders trading at Aprea Therapeutics
Over the last 5 years, insiders at Aprea Therapeutics have traded over $63,126,246 worth of Aprea Therapeutics stock and bought 2,073,560 units worth $29,606,912 . The most active insiders traders include Group, Llc Green Jeremy Red..., Vantage I, L.P.Versant Vant... és John B Iii Henneman. On average, Aprea Therapeutics executives and independent directors trade stock every 43 days with the average trade being worth of $420,918. The most recent stock trade was executed by John P. Hamill on 13 March 2024, trading 1,010 units of APRE stock currently worth $7,363.
What does Aprea Therapeutics do?
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors. The company's products pipeline also includes ATRN-Backup, an ATR inhibitor; ATRN-W1051 to treat anti-tumor activity; and ATRN-DDRi. Aprea Therapeutics, Inc. is based in Boston, Massachusetts.
What does Aprea Therapeutics's logo look like?
Complete history of Bernd Seizinger stock trades at Aptose Biosciences Inc és Aprea Therapeutics
Aprea Therapeutics executives and stock owners
Aprea Therapeutics executives and other stock owners filed with the SEC include:
-
Christian Schade,
Chairman of the Board, President, Chief Executive Officer -
Scott Coiante,
Chief Financial Officer, Senior Vice President, Secretary -
Eyal Attar,
Senior Vice President, Chief Medical Officer -
Christian S. Schade,
Pres, CEO & Chairman -
Dr. Eyal C. Attar M.D.,
Sr. VP & Chief Medical Officer -
Scott M. Coiante,
Sr. VP, Company Sec. & CFO -
John Henneman,
Lead Independent Director -
Bernd Seizinger,
Independent Director -
Guido Magni,
Independent Director -
Johan Christenson,
Independent Director -
Dr. Oren Gilad Ph.D.,
Co-Founder, Pres & Director -
Richard Peters,
Director -
Fouad Namouni,
Director -
Michael Kelly,
Director -
Gregory Wessels,
Chief Commercial Officer -
Gregory Korbel,
Vice President - Business Development -
Lars Abrahmsen,
Senior Vice President, Chief Scientific Officer -
Andrea Epstein,
Controller -
Dr. Michel Afargan Ph.D.,
Head of Pharmacology Devel. -
Hank Breslin,
Head of Medicinal Chemistry -
Dr. Rifat Pamukcu M.D.,
Chief Medical Advisor & Director -
Dr. Dansu Li Ph.D.,
Head of Technology -
Dr. Lars B. Abrahmsen,
Sr. VP & Chief Scientific Officer -
Dr. Gregory A. Korbel Ph.D.,
Sr. VP & Chief Bus. Officer -
Ventures Iv, L.P.5 Am Co In...,
-
Marc Duey,
Director -
Michael Grissinger,
Director -
Rifat Pamukcu,
Director -
Ventures Iv, L.P.5 Am Co In...,
-
V Luxco S.A R.L.Versant Ven...,
-
Oren Gilad,
President, CEO -
Investments Ab Karolinska D...,
-
Scott M Rocklage,
Director -
V Luxco S.A R.L.Versant Ven...,
-
Vantage I, L.P.Versant Vant...,
-
Group, Llc Green Jeremy Red...,
-
Vii, L.P.Health Cap Vii Gp ...,
-
Jonathan Hepple,
-
John P. Hamill,
SrVP/CFO/Prin Fin & Acct Ofcr -
Gabriela Gruia,
Director -
Jean Pierre Bizzari,
Director -
Nadeem Q. Mirza,
Chief Medical Officer